7MM atopic dermatitis market to be valued at $22.4b by 2033

The estimated drug-treated population may grow to over 25,100,000 people.

The atopic dermatitis (AD) market across seven major markets (7MM) is expected to reach $22.4b by 2033 at a compound annual growth rate of 10.2%, according to GlobalData.

The sector’s expansion is driven by a rise in treatment options, a high diagnosed prevalence, elevated treatment rates across all 7MM markets, the high annual cost of therapy for novel agents, and the introduction of therapies with novel mechanisms of action.

The estimated drug-treated population may grow to over 25,100,000 people in 7MM during the forecast period.

Meanwhile, the market was previously dominated by broad-acting immunomodulatory agents, which are being slowly replaced by more targeted agents, said Filippos Maniatis, Healthcare Analyst at GlobalData.

“This shift is likely due to better comprehension of the pathophysiology behind AD and the approval of several new systemic agents,” Maniatis added.

7MM = US, France, Germany, Italy, Spain, UK, and Japan